Director Desai Antal Rohit Makes Significant $10.5M Open Market Purchase in PROCEPT BioRobotics
PRCT sits 31% above its 52-week low of $19.35.
Summary
Director Antal Rohit Desai acquired over $10.4 million worth of PROCEPT BioRobotics common stock in open market transactions, indicating strong insider confidence.
Key Events · Ownership and Investor Activity · PRCT
-
Director's Substantial Stock Purchase
Director Antal Rohit Desai, through Kestrel Fund, L.P., purchased 426,262 shares of PROCEPT BioRobotics common stock in open market transactions.
-
Significant Investment Value
The total value of these purchases amounted to $10,482,943, executed across seven transactions between March 5 and March 9, 2026.
-
Timing Amidst Recent Company Updates
This significant insider buying follows the company's recent Q4 and full-year 2025 earnings reports and the presentation of a strategic plan projecting profitability by 2027.
Analysis · PRCT · Industrial Applications And Services
Director Antal Rohit Desai's substantial open market purchase of over $10 million in PROCEPT BioRobotics shares signals strong conviction in the company's prospects. This significant investment, made through Kestrel Fund, L.P., comes shortly after the company reported its Q4 and full-year 2025 results and outlined a strategic plan targeting profitability by 2027. The purchase, representing a notable percentage of the company's market capitalization, provides a positive counter-signal to the broader insider distribution trend observed over the last 90 days, suggesting the director sees value following recent corporate updates.
At the time of this filing, PRCT was trading at $25.26 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $19.35 to $66.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.